Skip to main content
OpenTrials
Completed

NCT Number: NCT03262337

TOURIST 2: Tracking Of Urgent Risks In Swiss Travelers

New mobile Health (mHealth) technology creates an opportunity to approach travel medicine research in a different way, revolutionising our understanding of risks to travellers. Using mHealth technology, the Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), developed a TRAVEL app in collaboration with the Eidgnössische Technische Hochschule (ETH) Zurich.

By using this new technology, an extensive collection of data (prospective collection of individual travel behaviour and experienced health events, mapping the travel itinerary via global positioning system (GPS), linking to publicly available local weather data and data on disease endemicity) can be combined and an unprecedented abundance of information on travel behaviour and experienced risks can be obtained. These data will allow a much better understanding of travel risk profiles using cluster analysis. By simultaneously recording health outcomes, the relationship between travel risk profiles and health events can be assessed. In this study, the investigators will address several major shortcomings in travel health in tropical and subtropical destinations by improving the understanding of poorly assessed and potentially underestimated health threats (e.g. risk of accidents and injury, mental health disorders), and travel risks specific to elderly travellers and travellers with chronic conditions. These findings will directly feed back into individual travel advice given by practitioners in Switzerland and finally world-wide.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Andreas Neumayr, Basel, Canton of Basel-City, Switzerland

Loading trial locations.

About this study

New mobile Health (mHealth) technology creates an opportunity to approach travel medicine research in a different way, revolutionising our understanding of risks to travellers. Using mHealth technology, the Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), developed a TRAVEL app in collaboration with the Eidgnössische Technische Hochschule (ETH) Zurich.

By using this new technology, an extensive collection of data (prospective collection of individual travel behaviour and experienced health events, mapping the travel itinerary via global positioning system (GPS), linking to publicly available local weather data and data on disease endemicity) can be combined and an unprecedented abundance of information on travel behaviour and experienced risks can be obtained. These data will allow a much better understanding of travel risk profiles using cluster analysis. By simultaneously recording health outcomes, the relationship between travel risk profiles and health events can be assessed. In this study, the investigators will address several major shortcomings in travel health in tropical and subtropical destinations by improving the understanding of poorly assessed and potentially underestimated health threats (e.g. risk of accidents and injury, mental health disorders), and travel risks specific to elderly travellers and travellers with chronic conditions.

1000 clients traveling to Thailand, China, India, Brazil, Peru or Tanzania will be recruited from the Travel Clinics in Zurich and Basel and through advertising at local travel agents and the universities of ETH and UZH from September 2017 until February 2019. After completing an intake at the clinic, participants will be given the option to use their own Smartphone for data collection, or to use a phone owned by the UZH-EBPI during travel. Participants will use a data collection app for questionnaire responses during and after travel including: a daily questionnaire on travel behaviors, daily symptoms questionnaire, and localization tracking, showing the participants' travel path and locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent
  • Traveler to Thailand, China, India, Brazil, Peru or Tanzania
  • German-speaking (level 3 or higher)
  • Literate (able to read and write in German - level 3 or higher)
  • Capable of operating Smartphone application for data collection
  • Traveling to Thailand, China, India, Brazil, Peru or Tanzania for ≤ 4 weeks

Exclusion criteria

  • not fulfilling inclusion criteria

Treatment and study plan

None, this is an observational study

Other

none, this is an observational study

Primary outcomes

  1. Self-reported risk behaviors

    Time frame: for a maximum of 4 weeks during travel

    The study participant will report on daily risk behaviors prior to, during and after travel in a daily app-based questionnaire

Secondary outcomes

  1. Self-reported symptoms

    Time frame: for a maximum of 4 weeks during travel

    The study participant will report on experienced symptoms/health events prior to, during and after travel in a daily app-based questionnaire

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Swiss Tropical & Public Health Institute

Registry information

Official study title

An Observational Study Using a Smartphone-app Supported Electronic Survey and Localization Tracking to Map Risk Behaviors and Symptoms of Swiss Travelers to Thailand, China, India, Brazil, Peru and Tanzania From 2 Swiss Travel Clinics

Acronym: TOURIST2

Important dates

Study start
2017
Primary completion
2019
Study completion
2021
First posted
Aug 25, 2017
Registry last updated
Apr 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.